Full Press Release Details
| Contact: | |
| Deanne Eagle - Media Relations | 917.837.5866 |
| Susan Roush - Investor Relations | 818.222.8330 |
NEURALSTEM GRANTS LICENSES FOR CENTRAL
THERAPY SURGICAL DEVICES TO CEDARS-SINAI MEDICAL CENTER
ROCKVILLE, MD, February 20,
2013 -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it has granted licenses to intellectual property surrounding its spinal
cord delivery platform, floating cannula, and method for delivering therapeutic agents to the spinal cord to Cedars-Sinai Medical
Center, a non-profit academic medical center located in Los Angeles, CA. The license agreements grant Cedars-Sinai Medical Center
the non-exclusive right to use the licensed intellectual property in academic research. This is the second group of licenses announced
by Neuralstem for these technologies. The financial terms of the agreement were not disclosed. Neuralstem holds the exclusive worldwide
licenses to the platform and cannula technologies.
The platform and cannula have been
used since 2010 in a Phase I ALS trial, sponsored by Neuralstem and recently completed at Emory University, covering the delivery
of Neuralstem's NSI-566 neural stem cells into the spinal cords of patients with amyotrophic lateral sclerosis (ALS or Lou
Gehrig's disease). Neuralstem recently received FDA approval to commence a Phase I trial in chronic spinal cord injury using
the platform and cannula technologies.
second set of licenses for our devices further demonstrates the growing acceptance of intraspinal delivery of therapeutics, once
thought impossible, in the treatment of spinal cord conditions and diseases," said Richard
Garr, Neuralstem's President and CEO. "We have shown that it can be done safely in our ALS trial in 15 patients, and
18 procedures, in which three patients successfully returned for second transplants. We plan to continue our licensing program
to industry and academia as they begin to explore the possibilities our technology has enabled."
Neuralstem's patented technology enables
the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control
the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed
dosing of the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred
to as Lou Gehrig's disease, in August 2012; the trial ends six months after that last surgery. Neuralstem has been awarded orphan
status designation by the FDA for its ALS cell therapy.
In addition to ALS, the company is
also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic
stroke and glioblastoma (brain cancer). The company received approval to commence a Phase I safety trial in chronic spinal cord
injury in January 2013.
Neuralstem also has the ability to
generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary
screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new
neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety
trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional
indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, and post-traumatic stress disorder (PTSD).
For more information, please visit
www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn
Cautionary Statement Regarding Forward
This news release may contain forward-looking
statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors
are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies
constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the
development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances,
need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors
that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports,
including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period
ended September 30, 2012.